TrialJournal of acquired immune deficiency syndromes (1999)2010

Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211).

Keith W Crawford et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.